Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Its proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and pioneers in chemistry, technology, and the life sciences, with a deep bench of expertise in drug development and commercialization spanning from large pharma to biotech innovators. The company is based in Sunnyvale, CA.
Subscribe to receive latest updates from the council
